Topotecan

Generic Name
Topotecan
Brand Names
Hycamtin, Potactasol, Topotecan Hospira
Drug Type
Small Molecule
Chemical Formula
C23H23N3O5
CAS Number
123948-87-8
Unique Ingredient Identifier
7M7YKX2N15
Background

An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.

Indication

用于小细胞肺癌(SCLC)和一线治疗失败的晚期转移性卵巢癌。

Associated Conditions
Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)
Associated Therapies
-

Phase I Trial of Periocular Topotecan in Retinoblastoma

Phase 1
Completed
Conditions
First Posted Date
2007-04-17
Last Posted Date
2008-05-02
Lead Sponsor
Hospital JP Garrahan
Target Recruit Count
5
Registration Number
NCT00460876
Locations
🇦🇷

Hospital JP Garrahan, Buenos Aires, CF, Argentina

Hycamtin Plus Carboplatin Versus Established Regimens for the Treatment of Ovarian Cancer Relapse

Phase 3
Completed
Conditions
Interventions
First Posted Date
2007-02-21
Last Posted Date
2016-09-22
Lead Sponsor
North Eastern German Society of Gynaecological Oncology
Target Recruit Count
550
Registration Number
NCT00437307
Locations
🇩🇪

Charité Campus Virchow Klinikum, Berlin, Germany

Brain Metastases In ErbB2-Positive Breast Cancer

First Posted Date
2007-02-19
Last Posted Date
2015-10-15
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
22
Registration Number
NCT00437073
Locations
🇸🇪

GSK Investigational Site, Uppsala, Sweden

Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin

First Posted Date
2007-02-19
Last Posted Date
2014-04-16
Lead Sponsor
Mayo Clinic
Target Recruit Count
18
Registration Number
NCT00436644
Locations
🇺🇸

Mayo Clinic Cancer Center, Rochester, Minnesota, United States

🇺🇸

Mayo Clinic Arizona, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic in Jacksonville, Jacksonville, Florida, United States

Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer

Phase 1
Completed
Conditions
First Posted Date
2006-11-09
Last Posted Date
2010-08-24
Lead Sponsor
Ascenta Therapeutics
Target Recruit Count
36
Registration Number
NCT00397293
Locations
🇷🇺

Research Center (16), Russia, Russian Federation

🇺🇦

Research Centers (8), Ukraine, Ukraine

Topotecan Pharmacokinetic Characterization Study

Phase 1
Completed
Conditions
Interventions
First Posted Date
2006-08-09
Last Posted Date
2017-11-17
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
15
Registration Number
NCT00361803
Locations
🇺🇸

GSK Investigational Site, Scottsdale, Arizona, United States

Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers

First Posted Date
2006-06-22
Last Posted Date
2015-05-15
Lead Sponsor
Benaroya Research Institute
Target Recruit Count
40
Registration Number
NCT00343044
Locations
🇺🇸

Puget Sound Oncology Consortium (PSOC), Seattle, Washington, United States

🇺🇸

Virginia Mason Medical Center, Seattle, Washington, United States

Concurrent Radiotherapy With Weekly Topotecan for Primary Treatment of Inoperable Localized Non-small Cell Lung Cancer

Phase 1
Completed
Conditions
First Posted Date
2006-05-08
Last Posted Date
2010-01-07
Lead Sponsor
University of New Mexico
Target Recruit Count
10
Registration Number
NCT00322751
Locations
🇺🇸

University of New Mexico, Albuquerque, New Mexico, United States

Efficacy Study of Weekly Topotecan With Cisplatin in Advanced Stage or Recurrent Cervical Cancer

Phase 1
Terminated
Conditions
First Posted Date
2006-05-08
Last Posted Date
2008-02-15
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
30
Registration Number
NCT00322920
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer

Phase 1
Completed
Conditions
First Posted Date
2006-05-03
Last Posted Date
2010-01-07
Lead Sponsor
University of New Mexico
Target Recruit Count
11
Registration Number
NCT00320983
Locations
🇺🇸

University of New Mexico, Albuquerque, New Mexico, United States

© Copyright 2024. All Rights Reserved by MedPath